Semaglutide vs Tirzepatide vs Retatrutide: Structure and Class Compared

This reference monograph compares three synthetic incretin-class research peptides — Semaglutide, Tirzepatide, and Retatrutide — strictly along structural and chemical lines: receptor classification, peptide class and backbone, molecular profile, and physical format. It is intended for research-use-only (RUO) contexts and makes no reference to dosing, administration, or physiological effects. The three are best understood as points on a single design continuum within the glucagon peptide superfamily: a GLP-1 mono-agonist, a GIP/GLP-1 dual agonist, and a GIP/GLP-1/glucagon tri-agonist. The sections below frame their similarities as a shared lipidated-peptide architecture and their differences as variations in receptor-target breadth, chain length, and conjugate chemistry — described analytically, with any unverified numeric constants deferred to lot-specific certificates of analysis.
How they compare
All three compounds belong to the incretin-mimetic class of synthetic peptides — single-chain analogs modeled on the glucagon/secretin (glucagon-superfamily) peptide backbone and characterized as receptor agonists associated with incretin-pathway and endocrinology research. Their principal distinction is receptor selectivity. Semaglutide is a mono-agonist directed at the GLP-1 (glucagon-like peptide-1) receptor. Tirzepatide is a dual agonist engineered to engage both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Retatrutide extends this design further as a tri-agonist reported to act at the GIP, GLP-1, and glucagon receptors. In research nomenclature this represents a progression from single- to dual- to triple-receptor targeting within one structural family, and it is the central axis along which the three are compared analytically. Structurally, each is a linear, chemically synthesized peptide rather than a recombinant protein, and all share the hallmark of lipidation: a fatty-diacid moiety conjugated to a lysine side chain through a spacer arrangement that includes a gamma-glutamate unit and short hydrophilic linkers. This acylation is a deliberate design feature reported to promote reversible binding to serum albumin in in-vitro and pharmacokinetic research systems, and it distinguishes these analogs from the shorter, non-acylated native incretin peptides. Semaglutide is the most compact of the three, comprising a 31-residue chain, whereas both tirzepatide and retatrutide are built on longer 39-residue backbones. Additional engineering common to the class includes substitution of non-coded amino acids such as alpha-aminoisobutyric acid (Aib) at positions prone to enzymatic cleavage, a modification associated in research assays with structural resistance to dipeptidyl peptidase-4 (DPP-4). On the molecular-profile axis, the peptides differ chiefly in chain length and in the composition of their fatty-acid conjugates and residue substitutions, which in turn are reflected in their differing molecular weights (semaglutide being the lightest as the shortest chain, with the two 39-residue analogs being heavier). In physical format the three are handled almost identically for research use. Analytical identity and purity for each are commonly established by reversed-phase HPLC and mass spectrometry. Thus the format comparison yields few practical differences — the meaningful contrasts lie in receptor-target breadth, chain length, and conjugate chemistry rather than in handling.
Frequently asked questions
How are Semaglutide, Tirzepatide, and Retatrutide classified?
All three are synthetic incretin-mimetic peptides within the glucagon peptide superfamily, characterized as receptor agonists associated with incretin-pathway research. They differ by target breadth: Semaglutide is a GLP-1 receptor mono-agonist, Tirzepatide a GIP/GLP-1 dual agonist, and Retatrutide a GIP/GLP-1/glucagon tri-agonist. This is a research-use-only classification and does not describe any physiological outcome.
What is the main structural difference between the three peptides?
Chain length and conjugate chemistry. Semaglutide is a 31-residue peptide, while Tirzepatide and Retatrutide are built on longer 39-residue backbones. All three are lipidated with a fatty-diacid moiety attached to a lysine side chain via a spacer that includes a gamma-glutamate unit and hydrophilic linkers, and all incorporate non-coded residues such as Aib associated with resistance to enzymatic cleavage in research assays.
Are they recombinant proteins or chemically synthesized peptides?
All three are chemically synthesized linear peptides rather than recombinant proteins. Their fatty-acid acylation and non-standard amino acid substitutions are introduced through synthetic peptide chemistry, a common design approach in this analog family.
Where can I find exact molecular weight and CAS number data?
Exact molecular constants are omitted here to avoid citing unverified values; confirm all numeric identity data against authoritative lot-specific records.
For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.